1	Abnormal	abnormal	_	_	_	_	_	_	_
2	NF-kappa	NF-kappa	_	_	_	_	_	_	_
3	B	B	_	_	_	_	_	_	_
4	activity	activity	_	_	_	_	_	_	_
5	in	in	_	_	_	_	_	_	_
6	T	t	_	_	_	_	_	_	_
7	lymphocytes	lymphocyte	_	_	_	_	_	_	_
8	from	from	_	_	_	_	_	_	_
9	patients	patient	_	_	_	_	_	_	_
10	with	with	_	_	_	_	_	_	_
11	systemic	systemic	_	_	_	_	_	_	_
12	lupus	lupus	_	_	_	_	_	_	_
13	erythematosus	erythematosus	_	_	_	_	_	_	_
14	is	be	_	_	_	_	_	_	_
15	associated	associate	_	_	_	_	_	_	_
16	with	with	_	_	_	_	_	_	_
17	decreased	decrease	_	_	_	_	_	_	_
18	p65-RelA	p65-rela	_	_	_	_	_	_	_
19	protein	protein	_	_	_	_	_	_	_
20	expression	expression	_	_	_	_	_	_	_
21	.	.	_	_	_	_	_	_	_

1	Numerous	numerous	_	_	_	_	_	_	_
2	cellular	cellular	_	_	_	_	_	_	_
3	and	and	_	_	_	_	_	_	_
4	biochemical	biochemical	_	_	_	_	_	_	_
5	abnormalities	abnormality	_	_	_	_	_	_	_
6	in	in	_	_	_	_	_	_	_
7	immune	immune	_	_	_	_	_	_	_
8	regulation	regulation	_	_	_	_	_	_	_
9	have	have	_	_	_	_	_	_	_
10	been	be	_	_	_	_	_	_	_
11	described	describe	_	_	_	_	_	_	_
12	in	in	_	_	_	_	_	_	_
13	patients	patient	_	_	_	_	_	_	_
14	with	with	_	_	_	_	_	_	_
15	systemic	systemic	_	_	_	_	_	_	_
16	lupus	lupus	_	_	_	_	_	_	_
17	erythematosus	erythematosus	_	_	_	_	_	_	_
18	(	(	_	_	_	_	_	_	_
19	SLE	SLE	_	_	_	_	_	_	_
20	)	)	_	_	_	_	_	_	_
21	,	,	_	_	_	_	_	_	_
22	including	include	_	_	_	_	_	_	_
23	surface	surface	_	_	_	_	_	_	_
24	Ag	ag	_	_	_	_	_	_	_
25	receptor-initiated	receptor-initiated	_	_	_	_	_	_	_
26	signaling	signaling	_	_	_	_	_	_	_
27	events	event	_	_	_	_	_	_	_
28	and	and	_	_	_	_	_	_	_
29	lymphokine	lymphokine	_	_	_	_	_	_	_
30	production	production	_	_	_	_	_	_	_
31	.	.	_	_	_	_	_	_	_

1	Because	because	_	_	_	_	_	_	_
2	NF-kappa	NF-kappa	_	_	_	_	_	_	_
3	B	B	_	_	_	_	_	_	_
4	contributes	contribute	_	_	_	_	_	_	_
5	to	to	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	transcription	transcription	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	numerous	numerous	_	_	_	_	_	_	_
10	inflammatory	inflammatory	_	_	_	_	_	_	_
11	genes	gene	_	_	_	_	_	_	_
12	and	and	_	_	_	_	_	_	_
13	has	have	_	_	_	_	_	_	_
14	been	be	_	_	_	_	_	_	_
15	shown	show	_	_	_	_	_	_	_
16	to	to	_	_	_	_	_	_	_
17	be	be	_	_	_	_	_	_	_
18	a	a	_	_	_	_	_	_	_
19	molecular	molecular	_	_	_	_	_	_	_
20	target	target	_	_	_	_	_	_	_
21	of	of	_	_	_	_	_	_	_
22	antiinflammatory	antiinflammatory	_	_	_	_	_	_	_
23	drugs	drug	_	_	_	_	_	_	_
24	,	,	_	_	_	_	_	_	_
25	we	we	_	_	_	_	_	_	_
26	sought	seek	_	_	_	_	_	_	_
27	to	to	_	_	_	_	_	_	_
28	characterize	characterize	_	_	_	_	_	_	_
29	the	the	_	_	_	_	_	_	_
30	functional	functional	_	_	_	_	_	_	_
31	role	role	_	_	_	_	_	_	_
32	of	of	_	_	_	_	_	_	_
33	the	the	_	_	_	_	_	_	_
34	NF-kappa	NF-kappa	_	_	_	_	_	_	_
35	B	B	_	_	_	_	_	_	_
36	protein	protein	_	_	_	_	_	_	_
37	complex	complex	_	_	_	_	_	_	_
38	in	in	_	_	_	_	_	_	_
39	lupus	lupus	_	_	_	_	_	_	_
40	T	t	_	_	_	_	_	_	_
41	cells	cell	_	_	_	_	_	_	_
42	.	.	_	_	_	_	_	_	_

1	Freshly	freshly	_	_	_	_	_	_	_
2	isolated	isolate	_	_	_	_	_	_	_
3	T	t	_	_	_	_	_	_	_
4	cells	cell	_	_	_	_	_	_	_
5	from	from	_	_	_	_	_	_	_
6	lupus	lupus	_	_	_	_	_	_	_
7	patients	patient	_	_	_	_	_	_	_
8	,	,	_	_	_	_	_	_	_
9	rheumatoid	rheumatoid	_	_	_	_	_	_	_
10	arthritis	arthritis	_	_	_	_	_	_	_
11	(	(	_	_	_	_	_	_	_
12	RA	RA	_	_	_	_	_	_	_
13	)	)	_	_	_	_	_	_	_
14	patients	patient	_	_	_	_	_	_	_
15	,	,	_	_	_	_	_	_	_
16	and	and	_	_	_	_	_	_	_
17	normal	normal	_	_	_	_	_	_	_
18	individuals	individual	_	_	_	_	_	_	_
19	were	be	_	_	_	_	_	_	_
20	activated	activate	_	_	_	_	_	_	_
21	physiologically	physiologically	_	_	_	_	_	_	_
22	via	via	_	_	_	_	_	_	_
23	the	the	_	_	_	_	_	_	_
24	TCR	TCR	_	_	_	_	_	_	_
25	with	with	_	_	_	_	_	_	_
26	anti-CD3	anti-cd3	_	_	_	_	_	_	_
27	and	and	_	_	_	_	_	_	_
28	anti-CD28	anti-cd28	_	_	_	_	_	_	_
29	Abs	ab	_	_	_	_	_	_	_
30	to	to	_	_	_	_	_	_	_
31	assess	assess	_	_	_	_	_	_	_
32	proximal	proximal	_	_	_	_	_	_	_
33	membrane	membrane	_	_	_	_	_	_	_
34	signaling	signaling	_	_	_	_	_	_	_
35	,	,	_	_	_	_	_	_	_
36	and	and	_	_	_	_	_	_	_
37	with	with	_	_	_	_	_	_	_
38	PMA	PMA	_	_	_	_	_	_	_
39	and	and	_	_	_	_	_	_	_
40	a	a	_	_	_	_	_	_	_
41	calcium	calcium	_	_	_	_	_	_	_
42	ionophore	ionophore	_	_	_	_	_	_	_
43	(	(	_	_	_	_	_	_	_
44	A23187	A23187	_	_	_	_	_	_	_
45	)	)	_	_	_	_	_	_	_
46	to	to	_	_	_	_	_	_	_
47	bypass	bypass	_	_	_	_	_	_	_
48	membrane-mediated	membrane-mediated	_	_	_	_	_	_	_
49	signaling	signaling	_	_	_	_	_	_	_
50	events	event	_	_	_	_	_	_	_
51	.	.	_	_	_	_	_	_	_

1	We	we	_	_	_	_	_	_	_
2	measured	measure	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	NF-kappa	NF-kappa	_	_	_	_	_	_	_
5	B	B	_	_	_	_	_	_	_
6	binding	binding	_	_	_	_	_	_	_
7	activity	activity	_	_	_	_	_	_	_
8	in	in	_	_	_	_	_	_	_
9	nuclear	nuclear	_	_	_	_	_	_	_
10	extracts	extract	_	_	_	_	_	_	_
11	by	by	_	_	_	_	_	_	_
12	gel	gel	_	_	_	_	_	_	_
13	shift	shift	_	_	_	_	_	_	_
14	analysis	analysis	_	_	_	_	_	_	_
15	.	.	_	_	_	_	_	_	_

1	When	when	_	_	_	_	_	_	_
2	compared	compare	_	_	_	_	_	_	_
3	with	with	_	_	_	_	_	_	_
4	normal	normal	_	_	_	_	_	_	_
5	cells	cell	_	_	_	_	_	_	_
6	,	,	_	_	_	_	_	_	_
7	the	the	_	_	_	_	_	_	_
8	activation	activation	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	NF-kappa	NF-kappa	_	_	_	_	_	_	_
11	B	B	_	_	_	_	_	_	_
12	activity	activity	_	_	_	_	_	_	_
13	in	in	_	_	_	_	_	_	_
14	SLE	SLE	_	_	_	_	_	_	_
15	patients	patient	_	_	_	_	_	_	_
16	was	be	_	_	_	_	_	_	_
17	significantly	significantly	_	_	_	_	_	_	_
18	decreased	decrease	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	SLE	SLE	_	_	_	_	_	_	_
21	,	,	_	_	_	_	_	_	_
22	but	but	_	_	_	_	_	_	_
23	not	not	_	_	_	_	_	_	_
24	in	in	_	_	_	_	_	_	_
25	RA	RA	_	_	_	_	_	_	_
26	,	,	_	_	_	_	_	_	_
27	patients	patient	_	_	_	_	_	_	_
28	.	.	_	_	_	_	_	_	_

1	NF-kappa	NF-kappa	_	_	_	_	_	_	_
2	B	B	_	_	_	_	_	_	_
3	binding	binding	_	_	_	_	_	_	_
4	activity	activity	_	_	_	_	_	_	_
5	was	be	_	_	_	_	_	_	_
6	absent	absent	_	_	_	_	_	_	_
7	in	in	_	_	_	_	_	_	_
8	several	several	_	_	_	_	_	_	_
9	SLE	sle	_	_	_	_	_	_	_
10	patients	patient	_	_	_	_	_	_	_
11	who	who	_	_	_	_	_	_	_
12	were	be	_	_	_	_	_	_	_
13	not	not	_	_	_	_	_	_	_
14	receiving	receive	_	_	_	_	_	_	_
15	any	any	_	_	_	_	_	_	_
16	medication	medication	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	including	include	_	_	_	_	_	_	_
19	corticosteroids	corticosteroid	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

1	Also	also	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	NF-kappa	NF-kappa	_	_	_	_	_	_	_
4	B	B	_	_	_	_	_	_	_
5	activity	activity	_	_	_	_	_	_	_
6	remained	remain	_	_	_	_	_	_	_
7	absent	absent	_	_	_	_	_	_	_
8	in	in	_	_	_	_	_	_	_
9	follow-up	follow-up	_	_	_	_	_	_	_
10	studies	study	_	_	_	_	_	_	_
11	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	supershift	supershift	_	_	_	_	_	_	_
3	experiments	experiment	_	_	_	_	_	_	_
4	using	use	_	_	_	_	_	_	_
5	specific	specific	_	_	_	_	_	_	_
6	Abs	ab	_	_	_	_	_	_	_
7	,	,	_	_	_	_	_	_	_
8	we	we	_	_	_	_	_	_	_
9	showed	show	_	_	_	_	_	_	_
10	that	that	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	in	in	_	_	_	_	_	_	_
13	the	the	_	_	_	_	_	_	_
14	group	group	_	_	_	_	_	_	_
15	of	of	_	_	_	_	_	_	_
16	SLE	sle	_	_	_	_	_	_	_
17	patients	patient	_	_	_	_	_	_	_
18	who	who	_	_	_	_	_	_	_
19	displayed	display	_	_	_	_	_	_	_
20	undetectable	undetectable	_	_	_	_	_	_	_
21	NF-kappa	NF-kappa	_	_	_	_	_	_	_
22	B	B	_	_	_	_	_	_	_
23	activity	activity	_	_	_	_	_	_	_
24	,	,	_	_	_	_	_	_	_
25	p65	p65	_	_	_	_	_	_	_
26	complexes	complex	_	_	_	_	_	_	_
27	were	be	_	_	_	_	_	_	_
28	not	not	_	_	_	_	_	_	_
29	formed	form	_	_	_	_	_	_	_
30	.	.	_	_	_	_	_	_	_

1	Finally	finally	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	immunoblot	immunoblot	_	_	_	_	_	_	_
4	analysis	analysis	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	nuclear	nuclear	_	_	_	_	_	_	_
7	extracts	extract	_	_	_	_	_	_	_
8	showed	show	_	_	_	_	_	_	_
9	decreased	decrease	_	_	_	_	_	_	_
10	or	or	_	_	_	_	_	_	_
11	absent	absent	_	_	_	_	_	_	_
12	p65	p65	_	_	_	_	_	_	_
13	protein	protein	_	_	_	_	_	_	_
14	levels	level	_	_	_	_	_	_	_
15	.	.	_	_	_	_	_	_	_

1	As	as	_	_	_	_	_	_	_
2	p65	p65	_	_	_	_	_	_	_
3	complexes	complex	_	_	_	_	_	_	_
4	are	be	_	_	_	_	_	_	_
5	transcriptionally	transcriptionally	_	_	_	_	_	_	_
6	active	active	_	_	_	_	_	_	_
7	in	in	_	_	_	_	_	_	_
8	comparison	comparison	_	_	_	_	_	_	_
9	to	to	_	_	_	_	_	_	_
10	the	the	_	_	_	_	_	_	_
11	p50	p50	_	_	_	_	_	_	_
12	homodimer	homodimer	_	_	_	_	_	_	_
13	,	,	_	_	_	_	_	_	_
14	this	this	_	_	_	_	_	_	_
15	novel	novel	_	_	_	_	_	_	_
16	finding	finding	_	_	_	_	_	_	_
17	may	may	_	_	_	_	_	_	_
18	provide	provide	_	_	_	_	_	_	_
19	insight	insight	_	_	_	_	_	_	_
20	on	on	_	_	_	_	_	_	_
21	the	the	_	_	_	_	_	_	_
22	origin	origin	_	_	_	_	_	_	_
23	of	of	_	_	_	_	_	_	_
24	abnormal	abnormal	_	_	_	_	_	_	_
25	cytokine	cytokine	_	_	_	_	_	_	_
26	or	or	_	_	_	_	_	_	_
27	other	other	_	_	_	_	_	_	_
28	gene	gene	_	_	_	_	_	_	_
29	transcription	transcription	_	_	_	_	_	_	_
30	in	in	_	_	_	_	_	_	_
31	SLE	sle	_	_	_	_	_	_	_
32	patients	patient	_	_	_	_	_	_	_
33	.	.	_	_	_	_	_	_	_

